New Horizon Health

New Horizon Health FCF Conversion

Delisted·Feb 9, 2026

The FCF Conversion Rate (FCF/EBITDA) of New Horizon Health (6606.HK) as of Oct 22, 2026 is 588.58 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 12.61 % — a change of 4,567.41% (higher).

FCF Conversion

588.58 %

YoY

4,567.41%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of New Horizon Health is 2022 588.58 % . FCF Conversion Rate (FCF/EBITDA) of New Horizon Health was 2021 12.61 % . It decreases by 4,567.41% higher compared to the previous year.

The New Horizon Health FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
32.52 CNY
Jan 1, 2019
104.98 CNY
Jan 1, 2020
19.82 CNY
Jan 1, 2021
12.61 CNY
Jan 1, 2022
588.58 CNY
The New Horizon Health FCF Conversion history
YEARFCF ConversionYoY
588.58 %+4,567.41%
12.61 %-36.39%
19.82 %-81.12%
104.98 %+222.78%
32.52 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

New Horizon Health Stock analysis

What does New Horizon Health do? New Horizon Health Ltd. generates revenue through the distribution of its ColoClear and Pupu tube products via its own network, contracted sales organisations (CSOs), and e-platforms managed by healthcare clinics. The company also develops Youyou Tube, a stool-based self-checking gastric cancer screening test, and CerviClear, a non-invasive urine cervical cancer home screening test, which are currently under development. Its primary customers include healthcare clinics and end-users seeking non-invasive cancer screening solutions. The firm's product portfolio focuses on innovative medical screening tools, targeting the growing demand for accessible and user-friendly health diagnostics. By leveraging its internal sales channels and partnerships with CSOs, New Horizon Health Ltd. ensures broad market reach for its products. The company's development of Youyou Tube and CerviClear reflects its strategic emphasis on expanding into high-need areas of cancer prevention and early detection. Revenue streams are derived from the sale of ColoClear and Pupu tube products, with future potential from the commercialization of Youyou Tube and CerviClear once development is complete. The company's business model relies on direct and indirect sales channels to healthcare providers and consumers, positioning it within the medical diagnostics sector. New Horizon Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about New Horizon Health stock

FCF Conversion Rate (FCF/EBITDA) of New Horizon Health is 588.58 % in 2022.

FCF Conversion Rate (FCF/EBITDA) of New Horizon Health changed from 12.61 % to 588.58 %, representing a 4,567.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) New Horizon Health since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s New Horizon Health with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — New Horizon Health

All Key Metrics — New Horizon Health